For years, doctors treating acute myeloid leukemia with a common class of targeted drugs believed they understood exactly how those medications worked: block a mutated protein called FLT3, and leukemia cells trigger their own programmed self-destruct sequence. A study published August 7, 2026, in the journal Nature Cell Biology, from researchers at Baylor College of Medicine and collaborating institutions, reveals that story was only half complete, and the missing half comes with a genuinely unexpected complication involving an ordinary dietary vitamin.

A cancer with a well-known genetic weak point

Acute myeloid leukemia, commonly abbreviated AML, is an aggressive blood cancer in which abnormal myeloid cells accumulate in the bone marrow, crowding out and interfering with the body's ability to produce normal, healthy blood cells. Among AML's various genetic drivers, mutations affecting FLT3, a receptor tyrosine kinase that transmits growth and survival signals to cells, rank among the most common alterations found in the disease.

Drugs designed to inhibit mutant FLT3, including a medication called gilteritinib, have already reshaped treatment for this specific genetic subset of AML patients. According to corresponding author Dr. Daisuke Nakada, the Henry and Emma Meyer Professor in Molecular and Human Genetics at Baylor, the established understanding of how these drugs worked was straightforward: "FLT3 mutations are one of the most common genetic drivers of AML. Other researchers have shown that inhibiting FLT3 stops AML cells from dividing and kills them by activating a self-destruct mechanism called apoptosis."

Why that established story left an important gap

That existing understanding, while accurate as far as it went, didn't explain a persistent clinical problem that has limited these drugs' long-term effectiveness. As Nakada put it, "like many other cancer therapies, resistance to FLT3 inhibitors and relapse are common." Patients frequently respond well to treatment initially, only to see their leukemia eventually develop resistance and return, a pattern common across many targeted cancer therapies but one that has remained particularly stubborn in FLT3-mutant AML specifically.

That gap between initial effectiveness and eventual resistance is precisely what motivated Nakada and his colleagues to investigate whether FLT3 inhibitors might be killing leukemia cells through an entirely separate mechanism running alongside the already-understood apoptosis pathway, one that resistant cells might eventually learn to evade independently from however they evade the apoptosis pathway alone.

Discovering a second, more violent form of cell death

The research team's investigation revealed exactly that: FLT3 inhibitors also trigger ferroptosis, a distinct and considerably more destructive form of cell death driven by the uncontrolled oxidation of cellular lipids, essentially a runaway chain reaction of fat molecules breaking down within the cell until the cell's structural integrity collapses entirely. Ferroptosis operates through fundamentally different cellular machinery than apoptosis, meaning a leukemia cell that has developed resistance mechanisms specifically tailored to block apoptosis might remain entirely vulnerable to this second, ferroptosis-driven attack, and vice versa.

The specific molecular pathway the researchers uncovered involves selenoproteins, a category of proteins that require the trace element selenium for their proper function. One selenoprotein in particular, GPX4, plays a central protective role against ferroptosis under normal cellular conditions, functioning as a kind of built-in brake preventing the runaway lipid oxidation that defines the ferroptosis process. The research team found that FLT3-mutant leukemia cells depend heavily on a process called selenocysteine recoding to keep that protective GPX4 pathway functioning, and that FLT3 inhibitor treatment disrupts this dependency, pushing affected cells toward ferroptosis as a second, independent kill mechanism layered on top of the previously understood apoptosis pathway.

How leukemia cells might be escaping treatment

That newly identified pathway also offered researchers a plausible explanation for at least part of the resistance problem that has long frustrated clinicians treating FLT3-mutant AML. According to the study's findings, leukemia cells appear capable of escaping treatment in part by boosting activity within this same selenoprotein pathway, effectively reinforcing their GPX4-based protection against ferroptosis even while remaining exposed to ongoing FLT3 inhibitor treatment. If a resistant leukemia cell population manages to strengthen this specific protective mechanism sufficiently, it could theoretically continue surviving FLT3 inhibitor exposure even after losing whatever vulnerability initially made it susceptible to the drug's better-understood apoptosis-triggering effect.

The vitamin E complication nobody was expecting

Perhaps the most immediately practical, and genuinely surprising, finding in the entire study involves an ordinary dietary supplement. Nakada and his colleagues discovered that dietary vitamin E, a well-known antioxidant that works specifically by attenuating ferroptosis, can markedly reduce the effectiveness of gilteritinib treatment. Because vitamin E directly counteracts the same lipid oxidation process that drives ferroptosis, high vitamin E intake appears capable of partially protecting leukemia cells from the very cell-death pathway this class of drugs depends on for a meaningful share of its therapeutic effect.

That finding carries direct, actionable relevance for AML patients currently undergoing FLT3 inhibitor treatment. Vitamin E supplements are widely available, inexpensive, and commonly taken by patients for a range of general wellness reasons entirely unrelated to their cancer treatment, meaning a patient could plausibly be undermining part of their own leukemia therapy's effectiveness without any awareness that a routine supplement was interfering with their prescribed medication's underlying mechanism.

Why this discovery points toward better treatment, not less treatment

It's worth being precise about what this study actually demonstrates and what it doesn't. The researchers aren't suggesting FLT3 inhibitors are less effective than previously understood; if anything, the discovery that these drugs work through two independent cell-death pathways rather than one suggests they may be more broadly effective against genetically diverse leukemia cell populations than researchers previously appreciated. What the study does clarify is why resistance and relapse remain common despite that dual mechanism, and it identifies a specific, targetable pathway, the selenoprotein-dependent ferroptosis defense system, that future combination therapies could potentially exploit to overcome that resistance directly.

A treatment strategy that deliberately pairs FLT3 inhibitors with a second drug designed to block the selenoprotein pathway's protective effect, rather than relying on FLT3 inhibition alone, could in principle push more resistant leukemia cells toward ferroptosis even after they've already adapted to survive the apoptosis-triggering side of treatment. That kind of combination approach represents a considerably more precise strategy than simply increasing FLT3 inhibitor dosing alone, since it targets the specific resistance mechanism the cells are actually using rather than simply applying more pressure through the same single pathway.

What this means for patients and clinicians right now

Given the vitamin E finding's immediate practical relevance, patients currently receiving FLT3 inhibitor treatment for AML, or their treating oncologists, may want to specifically discuss whether high-dose vitamin E supplementation could be interfering with treatment effectiveness, a conversation this study gives considerably more concrete scientific grounding than existed previously. Beyond that immediate clinical consideration, the broader scientific contribution here lies in giving researchers a genuinely new therapeutic target, the selenoprotein-ferroptosis pathway, to pursue in developing combination treatments aimed specifically at overcoming the resistance and relapse problem that has limited FLT3 inhibitors' long-term effectiveness since they first entered clinical use.

The research was supported by multiple grants from the National Institutes of Health, along with funding from the Leukemia and Lymphoma Society, the Uehara Memorial Foundation, and the MD Anderson AML/MDS Moonshot Program, reflecting the kind of substantial, multi-institutional backing typically associated with findings researchers consider likely to meaningfully influence future treatment development.

---

*Sources cited in this article include the peer-reviewed study "Targeting oncogenic FLT3 uncovers a ferroptosis vulnerability through selenocysteine recoding in acute myeloid leukaemia," published August 7, 2026, in Nature Cell Biology, and reporting from EurekAlert, Bioengineer.org, News-Medical.net, MedicalXpress, and Mirage News featuring statements from corresponding author Dr. Daisuke Nakada of Baylor College of Medicine. All figures reflect reporting available as of August 7, 2026.*